Quantum News
Sign InSign Up
Back to News
research

Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Summit Therapeutics reported Q4 2025 earnings with zero revenue, missing estimates by $76.6 million, and a $0.29 per-share loss, worse than expected by $0.27. Leadership emphasized pipeline progress, including its lead candidate ivonescimab, a bispecific antibody for cancer, now in late-stage trials with potential 2026 regulatory filings. The company highlighted a $150 million cash runway through mid-2027, prioritizing R&D over revenue generation amid ongoing clinical trials. Executives addressed investor concerns about trial delays, citing manufacturing optimizations and regulatory discussions as key factors in adjusted timelines. Co-CEOs Duggan and Zanganeh reaffirmed strategic focus on oncology and rare diseases, downplaying near-term profitability in favor of long-term pipeline value.
AI Audio Summary
0:00 / 0:00
Click to play
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript

Summarize this article with:

ChatGPTChatGPTPerplexityPerplexityClaudeClaudeGrokGrok

SA Transcripts158.57K FollowersFollow5ShareSaveCommentsQ4: 2026-02-23 Earnings SummaryInsightsTranscript InsightsPlay CallPlay CallEPS of -$0.29 misses by $0.27 | Revenue of $0.00 misses by $76.60M Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call February 23, 2026 4:30 PM EST Company Participants Dave Gancarz - Chief Business & Strategy OfficerMahkam Zanganeh - Co-CEO, President & DirectorManmeet Soni - COO, CFO & DirectorAllen Yang - Head of R&D StrategyRobert Duggan - Co-CEO & Executive Chairman Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research DivisionBradley Canino - Guggenheim Securities, LLC, Research DivisionTyler Van Buren - TD Cowen, Research DivisionAsthika Goonewardene - Truist Securities, Inc., Research DivisionXiaochuan Dai - UBS Investment Bank, Research DivisionMitchell Kapoor - H.C. Wainwright & Co, LLC, Research DivisionEric Schmidt - Cantor Fitzgerald & Co., Research DivisionFaisal Khurshid Presentation Operator Good afternoon, and welcome to Summit Therapeutics Q4 and Year-End 2025 Earnings Call. [Operator Instructions] We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the company's website for updates. Please note that today's call is being recorded. [Operator Instructions] At this time, I would like to turn the call over to Dave Gancarz at Summit Therapeutics, Chief Business and Strategy Officer. You may proceed. Dave GancarzChief Business & Strategy Officer Good afternoon, and thank you for joining us. On today's call, we will provide an update on our fourth quarter and year-end 2025 financial results and operational progress. This afternoon's press release is available on our website, www.smmttx.com. Our Form 10-K was also filed today and is available on our website and via the SEC's website. Today's call is being simultaneously webcast, and an archived replay will also be made available later today on our website. Joining me on the call today is Bob Duggan, our Chairman of the Board and Co-Chief Executive Officer; Dr. Maky Zanganeh, our

Read Original

Source Information

Source: Seeking Alpha